Glioblastoma multiforme Clinical Trials

A listing of Glioblastoma multiforme medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 140 clinical trials
Featured trial
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209) (FIGHT-209)

This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblatoma (GBM) or other primary CNS tumors with an activating FGFR1-3 mutation or fusion/rearrangement

FGFR1
measurable disease
ccnu
oligodendroglioma
temozolomide
  • 3 views
  • 22 Oct, 2022
  • 27 locations
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

The purpose of this study is to evaluate the efficacy and safety of GX-I7 in combination with bevacizumab in subjects with recurrent glioblastoma.

  • 0 views
  • 04 Oct, 2022
  • 1 location
B7-H3 Chimeric Antigen Receptor T Cells (B7-H3CART) in Recurrent Glioblastoma Multiforme

of adult subjects with recurrent IDH wild-type GBM using a standard 3+3 dose escalation design.

  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 07 Oct, 2022
  • 1 location
Phase 2 Study of CAN008 in Subjects With GBM

therapy in newly-diagnosed subjects with glioblastoma who have undergone surgical excision.

  • 4 views
  • 04 Oct, 2022
  • 1 location
SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE) (SURVIVE)

glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care

  • 21 views
  • 07 Oct, 2022
  • 10 locations
Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma

Glioblastoma is a highly aggressive and fatal form of primary malignant brain tumor with limited treatment options. fb-PMT affects a large group of cancer cell signaling pathways and thus may be

karnofsky performance status
cancer
brain tumor
recurrent glioblastoma
  • 0 views
  • 04 Oct, 2022
  • 1 location
  • 0 views
  • 22 Oct, 2022
  • 1 location
Pilot Trial of Spectroscopic MRI-guided, Dose-Escalated Proton Radiation Therapy and Bevacizumab for Recurrent Glioblastoma

The purpose of this research is to find hidden cancer with an experimental magnetic resonance imaging (MRI) scan called spectroscopic magnetic resonance imaging (sMRI). That spectroscopic MRI scan will be used to increase the area of the brain receiving radiation and then the dose of radiation in attempt to kill …

  • 0 views
  • 27 Oct, 2022
  • 1 location
Romiplostim for Thrombocytopenia Induced by Lomustine at First Progression of MGMT Promoter-methylated Glioblastoma: a Randomized Phase II Open Label Multicenter Study (RIGOLETTO)

Romiplostim for low platelets caused by lomustine chemotherapy in patients with first recurrence (growing back) of a brain tumor, glioblastoma that is MGMT methylated. Lomustine is an

  • 0 views
  • 17 Oct, 2022
  • 1 location